With patient safety becoming more critical than ever in today's evolving healthcare landscape, the demand for robust drug safety practices continues to surge.
Ichnos Glenmark Innovation (IGI), a global, fully integrated clinical- stage biotechnology company focused on developing multispecificsTM in oncology, today presented promising full dose-escalation results from its Phase 1 TRIgnite-1 study of ISB 2001
Biocon Pharma Limited, has received approval for its Liraglutide drug product (6 mg/ml solution for injection in pre-filled pen and cartridge), from the Drugs Controller General of India, CDSCO (Central Drugs Standard Control Organisation).